Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
Robert D HendersonJan M AgostiPamela A McCombeKathryn ThorpeSusan HeggieSaman HeshmatMark W ApplebyBrian W ZiegelaarDavid T CroweGarry L RedlichPublished in: Medicine (2021)
NCT03487263.